Davita Inc (NYSE:DVA) was the recipient of unusually large options trading activity on Wednesday. Investors acquired 3,355 call options on the company. This is an increase of 1,723% compared to the typical volume of 184 call options.
Shares of Davita (NYSE DVA) opened at $78.61 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.40 and a debt-to-equity ratio of 1.79. The stock has a market cap of $14,420.00, a PE ratio of 30.12 and a beta of 0.96. Davita has a fifty-two week low of $52.51 and a fifty-two week high of $80.71.
Davita (NYSE:DVA) last issued its earnings results on Tuesday, November 7th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.94 by ($0.13). The firm had revenue of $3.92 billion during the quarter, compared to the consensus estimate of $3.91 billion. Davita had a net margin of 3.40% and a return on equity of 13.31%. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.95 earnings per share. analysts predict that Davita will post 3.42 earnings per share for the current year.
Davita announced that its Board of Directors has initiated a share buyback plan on Tuesday, October 10th that permits the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization permits the company to purchase shares of its stock through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.
In related news, VP Leanne M. Zumwalt sold 949 shares of the company’s stock in a transaction on Friday, December 8th. The shares were sold at an average price of $68.19, for a total value of $64,712.31. Following the completion of the transaction, the vice president now directly owns 12,423 shares of the company’s stock, valued at approximately $847,124.37. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Javier Rodriguez sold 22,532 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $67.48, for a total transaction of $1,520,459.36. Following the completion of the transaction, the chief executive officer now directly owns 210,317 shares of the company’s stock, valued at $14,192,191.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 121,509 shares of company stock valued at $8,310,388. Company insiders own 2.10% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Coastline Trust Co raised its holdings in shares of Davita by 6.3% in the 4th quarter. Coastline Trust Co now owns 16,120 shares of the company’s stock valued at $1,165,000 after purchasing an additional 950 shares during the period. Creative Planning raised its holdings in shares of Davita by 8.6% in the 4th quarter. Creative Planning now owns 13,137 shares of the company’s stock valued at $949,000 after purchasing an additional 1,044 shares during the period. Founders Capital Management LLC raised its holdings in shares of Davita by 2.3% in the 3rd quarter. Founders Capital Management LLC now owns 95,939 shares of the company’s stock valued at $5,698,000 after purchasing an additional 2,115 shares during the period. CAPROCK Group Inc. raised its holdings in shares of Davita by 53.2% in the 4th quarter. CAPROCK Group Inc. now owns 6,290 shares of the company’s stock valued at $498,000 after purchasing an additional 2,183 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Davita in the 3rd quarter valued at about $154,000. 87.97% of the stock is currently owned by institutional investors.
DVA has been the subject of a number of recent research reports. TheStreet upgraded shares of Davita from a “c” rating to a “b-” rating in a research note on Thursday, January 4th. Citigroup upgraded shares of Davita from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $67.71 to $82.00 in a research note on Monday, December 11th. Bank of America upgraded shares of Davita from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $85.00 in a research note on Thursday, January 4th. Robert W. Baird restated a “buy” rating and set a $95.00 price objective (up from $82.00) on shares of Davita in a research note on Friday, January 12th. Finally, SunTrust Banks set a $70.00 price objective on shares of Davita and gave the stock a “hold” rating in a research note on Thursday, December 7th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $78.22.
ILLEGAL ACTIVITY WARNING: “Davita Sees Unusually High Options Volume (DVA)” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/20/davita-sees-unusually-high-options-volume-dva.html.
Davita Company Profile
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.